PDF herunterladen
Erfahrungsheilkunde 2012; 61(4): 208-213
DOI: 10.1055/s-0032-1314683
Erkrankungen der Frau
© Karl F. Haug Verlag MVS Medizinverlage Stuttgart GmbH & Co. KG

Phytotherapie versus Hormone bei klimakterischen Beschwerden

Karin Kraft
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. August 2012 (online)

    Lizenzen und Reprints

Zusammenfassung

Klimakterische Beschwerden können die Lebensqualität außerordentlich beeinträchtigen. Hormonersatztherapie ist zwar bei starken vasomotorischen Symptomen gut wirksam, jedoch haben klinische Studien gezeigt, dass sogar ihre kurzzeitige Anwendung erhebliche Risiken birgt. Die Einnahme von Phytotherapeutika, bei denen eine Wirksamkeit bei Wechseljahresbeschwerden bekannt ist, ist deshalb stark angestiegen. Klinische Studien haben inzwischen gezeigt, dass Präparate aus Mönchspfefferfrüchten, Rhapontikrhabarber, Traubensilberkerzenwurzelstock und Leinsamen sicher und hinsichtlich einer Reihe von Wechseljahressymptomen wirksam sind. Nahrungsergänzungsmitteln mit Soja-Isoflavonen oder Extrakten aus Rotklee scheinen ebenfalls geeignet zu sein.

Abstract

Climacteric discomforts can extremely influence the quality of life. The hormone replacement therapy is very effective in the case of severe vasomotory symptoms, but clinical studies have shown, that even the short-term application of this therapy involves considerable risks. Therefore, the taking of phytotherapeutic agents with a known efficiency in the case of climacteric discomforts has increased considerably. In the meantime, clinical studies have shown, that preparations from fruits of the monks pepper tree, rhubarb (rheum rhaponticum), cimicifuga racemosa, and linseed are safe and effective with respect to a number of climacteric symptoms. Food supplements with soy isoflavones or extracts from red clover also seem to be suitable.

Schlüsselwörter

Menopause - klimakterische Beschwerden - Hormonersatztherapie - HRT - Phytotherapie - Nahrungsergänzungsmittel

Keywords

Menopause - climacteric discomforts - hormone replacement therapy - HRT - phytotherapy - food supplements
 

  • Literatur

  • 1 Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold „HRT“. PLoS Medicine 2010; 7 (9) e1000335
    PubMedGoogle Scholar
  • 2 Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280 (7): 605-613
    CrossrefPubMedGoogle Scholar
  • 3 Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-333
    CrossrefPubMedGoogle Scholar
  • 4 Barnes BB, Steindorf K, Hein R et al. Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiol 2011; 35 (4): 345-352
    CrossrefPubMedGoogle Scholar
  • 5 Hormontherapie (HT) in der Peri- und Postmenopause. 2009 www.awmf.org/leitlinien/detail/ll/015-062.html
    PubMedGoogle Scholar
  • 6 Vitex. 2011 www.ema.europa.eu
    PubMedGoogle Scholar
  • 7 Daniele C et al. Vitex agnus castus: a systematic review of adverse events. Drug Safety 2005; 28 (4): 319-332
    CrossrefPubMedGoogle Scholar
  • 8 Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Women’s Health Gend-Based Med 2000; 9 (3): 315-320
    PubMedGoogle Scholar
  • 9 Halaska M, Raus K, Beles P et al. [Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo]. Ceska Gynekol 1998; 63 (5): 388-392
    PubMedGoogle Scholar
  • 10 Wuttke W, Jarry H, Christoffel V et al. Chaste tree (Vitex agnus-castus)--pharmacology and clinical indications. Phytomedicine 2003; 10 (4): 348-357
    Google Scholar
  • 11 He Z, Chen R, Zhou Y et al. Treatment for premenstrual syndrome with Vitex agnus castus: A prospective, randomized, multi-center placebo controlled study in China. Maturitas 2009; 63 (1): 99-103
    CrossrefPubMedGoogle Scholar
  • 12 Berger D, Schaffner W, Schrader E et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet 2000; 264 (3): 150-153
    CrossrefPubMedGoogle Scholar
  • 13 Doll M. [The premenstrual syndrome: effectiveness of Vitex agnus castus]. Medizinische Monatsschrift fur Pharmazeuten 2009; 32 (5): 186-191
    PubMedGoogle Scholar
  • 14 Van Die MD et al. Effects of a combination of Hypericum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis. J Altern Complement Med 2009; 15 (9): 1045-1048
    CrossrefPubMedGoogle Scholar
  • 15 Ma L, Lin S, Chen R et al. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol Endocrinol 2010; 26 (8): 612-616
    CrossrefPubMedGoogle Scholar
  • 16 Zamani M, Neghab N, Torabian S. Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta medica Iranica 2012; 50 (2): 101-106
    PubMedGoogle Scholar
  • 17 Milewicz AG, Gejdel E, Sworen H et al. Vitex agnus castus-Extrakt zur Behandlung von Regeltempoanomalien infolge latenter Hyperprolaktinämie. Arzneimittelforschung 1993; 43 (7): 752-756
    PubMedGoogle Scholar
  • 18 Kaszkin-Bettag M, Ventskovskiy BM, Solskyy S et al. Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms. Altern Ther Health Med 2009; 15 (1): 24-34
    PubMedGoogle Scholar
  • 19 Kaszkin-Bettag M, Ventskovskiy BM, Kravchenko A et al. The special extract ERr 731 of the roots of Rheum rhaponticum decreases anxiety and improves health state and general well-being in perimenopausal women. Menopause 2007; 14 (2): 270-283
    CrossrefPubMedGoogle Scholar
  • 20 Heger M, Ventskovskiy BM, Borzenko I et al. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. Menopause 2006; 13 (5): 744-759
    CrossrefPubMedGoogle Scholar
  • 21 Hasper I, Ventskovskiy BM, Rettenberger R et al. Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with menopausal symptoms. Menopause 2009; 16 (1): 117-131
    CrossrefPubMedGoogle Scholar
  • 22 Cicek SS, Khom S, Taferner B et al. Bioactivity-guided isolation of GABA(A) receptor modulating constituents from the rhizomes of Actaea racemosa. J Nat Prod 2010; 73 (12): 2024-2028
    CrossrefPubMedGoogle Scholar
  • 23 Jarry H, Metten M, Spengler B et al. In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas 2003; 44 Suppl 1 p. S 31-38
    CrossrefPubMedGoogle Scholar
  • 24 Reame NE, Lukacs JL, Padmanabhan V et al. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 2008; 15 (5): 832-840
    CrossrefPubMedGoogle Scholar
  • 25 Einbond LS, Wen-Cai Y, He K et al. Growth inhibitory activity of extracts and compounds from Cimicifuga species on human breast cancer cells. Phytomedicine 2008; 15 (6–7): 504-511
    CrossrefPubMedGoogle Scholar
  • 26 Garita-Hernandez M, Calzado MA, Caballero FJ et al. The growth inhibitory activity of the Cimicifuga racemosa extract Ze 450 is mediated through estrogen and progesterone receptors-independent pathways. Planta Med 2006; 72 (4): 317-323
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 27 Al-Akoum M, Dodin S, Akoum A. Synergistic cytotoxic effects of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. Can J Physiol Pharmacol 2007; 85 (11): 1153-1159
    CrossrefPubMedGoogle Scholar
  • 28 Hostanska K, Nisslein T, Freudenstein J et al. Inhibitory effect of an isopropanolic extract of black cohosh on the invasiveness of MDA-mB 231 human breast cancer cells. In vivo 2007; 21 (2): 349-355
    PubMedGoogle Scholar
  • 29 Hostanska K, Nisslein T, Freudenstein J et al. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Res Treat 2004; 84 (2): 151-160
    CrossrefPubMedGoogle Scholar
  • 30 Nasr A, Nafeh H. Influence of black cohosh (Cimicifuga racemosa) use by postmenopausal women on total hepatic perfusion and liver functions. Fertil Steril 2009; 92 (5): 1780-1782
    CrossrefPubMedGoogle Scholar
  • 31 Gurley BJ, Barone GW, Wlliams DK et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metabol Dispos 2006; 34 (1): 69-74
    PubMedGoogle Scholar
  • 32 Ross SM. Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms. Holist Nurs Pract 2012; 26 (1): 58-61
    PubMedGoogle Scholar
  • 33 Bai W, Henneicke-von Zepelin HH, Wang S et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007; 58 (1): 31-41
    CrossrefPubMedGoogle Scholar
  • 34 Oktem M, Eroglu D, Karahan HB et al. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther 2007; 24 (2): 448-461
    CrossrefPubMedGoogle Scholar
  • 35 Chung DJ, Kim HY, Park KH et al. Black cohosh and St. John’s wort (GYNO-Plus) for climacteric symptoms. Yonsei Med J 2007; 48 (2): 289-294
    CrossrefPubMedGoogle Scholar
  • 36 Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007; 23 (2): 117-122
    CrossrefPubMedGoogle Scholar
  • 37 Newton KM, Reed SD, LaCroix AZ et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006; 145 (12): 869-879
    CrossrefPubMedGoogle Scholar
  • 38 Uebelhack R, Blohmer JU, Graubaum HJ et al. Black cohosh and St. John’s wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006; 107 (2 Pt 1): 247-255
    CrossrefPubMedGoogle Scholar
  • 39 Rostock M, Fischer J, Mumm A et al. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study. Gynecol Endocrinol 2011; 27 (10): 844-848
    CrossrefPubMedGoogle Scholar
  • 40 Reed SD, Newton KM, LaCroix AZ et al. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008; 15(1): 51-58
    PubMedGoogle Scholar
  • 41 Spangler L, Newton KM, Grothaus LC et al. The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin. Maturitas 2007; 57 (2): 195-204
    CrossrefPubMedGoogle Scholar
  • 42 Hirschberg AL, Edlund M, Svane G et al. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause 2007; 14 (1): 89-96
    CrossrefPubMedGoogle Scholar
  • 43 Raus K, Brucker C, Gorkow C et al. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause 2006; 13 (4): 678-691
    CrossrefPubMedGoogle Scholar
  • 44 Wuttke W, Gorkow C, Seidlova-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 2006; 13 (2): 185-196
    CrossrefPubMedGoogle Scholar
  • 45 North American Menopause Society. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011; 18 (7): 732-753
    CrossrefPubMedGoogle Scholar
  • 46 Taku K, Melby MK, Kronenberg F et al. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause 2012; 19 (7): 776-790
    CrossrefPubMedGoogle Scholar
  • 47 Lipovac M, Chedraui P, Gruenhut C et al. The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women. Gynecol Endocrinol 2012; 28 (3): 203-207
    CrossrefPubMedGoogle Scholar
  • 48 Coon JT, Pittler MH, Ernst E. Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis. Phytomedicine 2007; 14 (2–3): 153-159
    CrossrefPubMedGoogle Scholar
  • 49 Pruthi S, Qin R, Terstreip SA et al. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause 2012; 19 (1): 48-53
    CrossrefPubMedGoogle Scholar
  • 50 Simbalista RL, Sauerbronn AV, Aldrighi JM et al. Consumption of a flaxseed-rich food is not more effective than a placebo in alleviating the climacteric symptoms of postmenopausal women. J Nutr 2010; 140 (2): 293-297
    CrossrefPubMedGoogle Scholar